EU accepts marketing application for Paratek’s antibiotic
European regulators have accepted an application from Paratek Pharmaceuticals seeking approval of the broad-spectrum antibiotic omadacycline for two types of infection.
Read More
Tag: Paratek
Green light for acne drug Seysara in the US
US regulators have approved Paratek’s Seysara for the treatment of acne in patients aged nine years or older.
Read More
Allergan reports success in late-stage acne trials
Dublin, Ireland-based drugmaker Allergan and US partner Paratek Pharmaceuticals have reported that two Phase III trials assessing sarecycline for the treatment of moderate to severe acne have hit their primary endpoints.
Read More
- CERo reports encouraging early data from phase 1 trial of CER‑1236
- ENA Respiratory begins dosing in phase 2 study of INNA‑051 nasal spray
- Argo Biopharma doses first patient in phase 2b trial of BW‑20829
- Akari files new patent and advances second ADC targeting CEACAM5
- BioMed X launches kidney disease project in partnership with the government of Barbados
